Iris Yuritzi Torres Deviana

Dr. Iris Yuritzi Torres Deviana


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
AGANTONIO ABAD GARCIA
ANTONIO ABAD GARCIA
MBMartiniano Bello
Martiniano Bello
MHMaricarmen Hernández-Rodríguez
Maricarmen Hernández-Rodríguez
Iris Yuritzi Torres DevianaIris Yuritzi Torres Deviana
Iris Yuritzi Torres Deviana
JGJuan Antonio Garcia
Juan Antonio Garcia
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua
Parkinson’s disease (PD) is one of the most prevalent and extensively studied neurodegenerative conditions. One of its most challenging clinical manifestations is the emergence of dyskinesias, characterized by involuntary movements that significantly impair patients’ quality of life. Meanwhile, boron, as a trace element, and boron-containing compounds have emerged as active modulators of neurotransmitter systems. To evaluate the effect of aryl-boroxazolidones on parkinsonism, the in vitro neurotoxicity of three boroxazolidones was assessed, along with the effects of two of them in mice with parkinsonism induced by MPTP administration. Two novel compounds demonstrated a limitation of parkinsonism, whereas risperidone reduced the beneficial effect of the tested boroxazolidones. The three boroxazolidones did not induce toxicity in neurons or glial cells at concentrations up to 100 µM. In silico analyses support the ability of BCC to act as ligands of dopamine and serotonin receptors. Taken together, these results suggest that the tested boroxazolidones are promising candidate agents, warranting further exploration for the treatment of PD.